Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct 25:12:258.
doi: 10.3389/fnmol.2019.00258. eCollection 2019.

The Role of Microglia and Astrocytes in Huntington's Disease

Affiliations

The Role of Microglia and Astrocytes in Huntington's Disease

Thulani H Palpagama et al. Front Mol Neurosci. .

Abstract

Huntington's disease (HD) is an autosomal dominant neurodegenerative disease. HD patients present with movement disorders, behavioral and psychiatric symptoms and cognitive decline. This review summarizes the contribution of microglia and astrocytes to HD pathophysiology. Neuroinflammation in the HD brain is characterized by a reactive morphology in these glial cells. Microglia and astrocytes are critical in regulating neuronal activity and maintaining an optimal milieu for neuronal function. Previous studies provide evidence that activated microglia and reactive astrocytes contribute to HD pathology through transcriptional activation of pro-inflammatory genes to perpetuate a chronic inflammatory state. Reactive astrocytes also display functional changes in glutamate and ion homeostasis and energy metabolism. Astrocytic and microglial changes may further contribute to the neuronal death observed with the progression of HD. Importantly, the degree to which these neuroinflammatory changes are detrimental to neurons and contribute to the progression of HD pathology is not well understood. Furthermore, recent observations provide compelling evidence that activated microglia and astrocytes exert a variety of beneficial functions that are essential for limiting tissue damage and preserving neuronal function in the HD brain. Therefore, a better understanding of the neuroinflammatory environment in the brain in HD may lead to the development of targeted and innovative therapeutic opportunities.

Keywords: astrocytes; huntington’s disease; microglia; neurodegeneration; neuroinflammation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Microglial and astrocytic contribution to neuronal death in Huntington’s disease (HD). Surveilling microglia are activated by stimulating molecules through NF-κB signaling, upregulation of PU1 and CCAT binding. Activated microglia and reactive astrocytes produce reactive oxygen species (ROS) and neurotoxic molecules (such as quinolinic acid) which can induce molecular processes leading to neuronal death. Stimulatory molecules also induce reactive astrogliosis that leads to the upregulation of pro-inflammatory cytokine production, glutamate excitotoxicity and hyperexcitability of neurons.
Figure 2
Figure 2
Immunomodulatory therapy for HD. Drugs acting on microglia, astrocytes and neurons reduce neuroinflammatory processes, promote neurotrophic support and sustain white matter integrity.

References

    1. Abbott N. J., Rönnbäck L., Hansson E. (2006). Astrocyte-endothelial interactions at the blood-brain barrier. Nat. Rev. Neurosci. 7, 41–53. 10.1038/nrn1824 - DOI - PubMed
    1. Allaman I., Bélanger M., Magistretti P. J. (2011). Astrocyte-neuron metabolic relationships: for better and for worse. Trends Neurosci. 34, 76–87. 10.1016/j.tins.2010.12.001 - DOI - PubMed
    1. Andrew S. E., Goldberg Y. P., Kremer B., Telenius H., Theilmann J., Adam S., et al. . (1993). The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington’s disease. Nat. Genet. 4, 398–403. 10.1038/ng0893-398 - DOI - PubMed
    1. Arzberger T., Krampfl K., Leimgruber S., Weindl A. (1997). Changes of NMDA receptor subunit (NR1, NR2B) and glutamate transporter (GLT1) mRNA expression in Huntington’s disease—an in situ hybridization study. J. Neuropathol. Exp. Neurol. 56, 440–454. 10.1097/00005072-199704000-00013 - DOI - PubMed
    1. Aziz N. A., Anguelova G. V., Marinus J., van Dijk J. G., Roos R. A. C. (2010). Autonomic symptoms in patients and pre-manifest mutation carriers of Huntington’s disease. Eur. J. Neurol. 17, 1068–1074. 10.1111/j.1468-1331.2010.02973.x - DOI - PubMed

LinkOut - more resources